An interventional study of SGRT in Lung Cancer, sponsored by Wake Forest University Health Sciences. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.
Sponsored by Wake Forest University Health Sciences · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies in Lung Neoplasms by Wake Forest University Health Sciences — 3 open to participants now, 6 under way, none of them phase 3. Lung Neoplasms · Wake Forest University Health Sciences.
Among the 36 studies in Lung Neoplasms by Wake Forest University Health Sciences, this one is the 17th largest by enrollment of the 31 interventional ones that give a count, is one of 6 that started in 2019, is one of 14 with no phase, and was the 28th registered.
5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.
Browse Lung Neoplasms studies →3 of the 36 studies in Lung Neoplasms by Wake Forest University Health Sciences are open now, in 1 country. Recruiting first, the newest first:
Wake Forest University Health Sciences · Sites in United States
Ages 50–77
Wake Forest University Health Sciences · Sites in United States
Ages 40–54 · Healthy volunteers
Wake Forest University Health Sciences · Sites in United States
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 11 · Phase 3 3
First in 1998; this study’s year is marked. 6 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 45 is below the median of 60 across 3,668 interventional studies indexed under Lung Neoplasms.
Median enrollment 46 across the 31 interventional studies, 55 across the 5 observational. Of the 27 that completed or were terminated, 13 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
Wake Forest University Health Sciences is the lead sponsor of 1,353 studies on the registry; 199 are open to participants now.
Of its 332 completed or terminated interventional studies of FDA-regulated products, 251 (76%) have results posted.
3 of the studies in Lung Neoplasms by Wake Forest University Health Sciences that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06383988Wake Forest University Health SciencesA Web-based Program to Help Caregivers of Lung Patients Learn About Available Supportive Care Resources | 2026-12-30 |
| NCT07322367Wake Forest University Health SciencesA Mobile Patient Health Technology Intervention for Improving Lung Cancer Screening Rates in Eligible High Risk Patients | 2027-01 |
| NCT07282444Wake Forest University Health SciencesA New Way to Share Radiation Therapy Plans Between Doctors, CORRECT Trial | 2027-11-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 36 studies in Lung Neoplasms by Wake Forest University Health Sciences, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a pilot study designed to to provide data and experience comparing two different techniques of breath hold SBRT treatments. The first technique will include SGRT, but with the assistance of implanted fiducials. Subjects will be treated with a breath hold technique utilizing SGRT, but will also be imaged during treatment with fiducial match. The second technique will utilize SGRT for breath hold treatments without the assistance of implanted fiducials/continuous imaging.
The study's primary objective is estimate the incidence of SBRT and fiducial-related pulmonary toxicities for subjects treated with SBRT who have tumors that move ≥ 1 cm in 3 different cohorts: 1) free breathing with SGRT 2) breath hold utilizing SGRT only; 3) breath hold utilizing SGRT in combination with implanted fiducials. Secondary objectives also include Estimate reliability of gated SBRT treatments utilizing SGRT vs. SGRT with fiducials estimating local control for SBRT in subjects treated in the three different cohorts, estimating overall survival, and evaluating quality of life. A safety objective of estimating acute and long-term grade 2 or higher non-hematologic toxicities attributed to SBRT/fiducial implantation in subjects treated in the three different cohorts will also be explored.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subject must meet all of the following applicable inclusion criteria to participate in this study:
Exclusion Criteria
Subjects meeting any of the criteria below may not participate in the study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Freebreathing SBRT with SGRT
Device: SGRT
Breath hold SBRT with SGRT
Device: SGRT
Breath hold SBRT with SGRT in combination with implanted fiducials
Device: SGRT
Surface Guided Radiation Therapy
Number of Participants With Grade 2 or Higher SBRT-related Pulmonary Toxicities as Assessed by NCI CTCAE v.5.0
A binary variable was determined for each participant indicating whether the participant experienced at least one grade 2 or higher pulmonary adverse event (according to NCI Common Terminology for Adverse Events version 5.0) during treatment or within 12 months after completion of SBRT that was determined to be related (possibly, probably, or definitely attributed) to SBRT.
Time frame: from date of SBRT start or fiducial placement to 12 months after completion of SBRT treatment
Number of Participants With Grade 2 or Higher Fiducial-related Pulmonary Toxicities as Assessed by NCI CTCAE v.5.0
A binary variable was determined for each participant indicating whether the participant experienced at least one grade 2 or higher pulmonary adverse event (according to NCI Common Terminology for Adverse Events version 5.0) during treatment or within 12 months after completion of SBRT that was determined to be related (possibly, probably, or definitely attributed) to implantation of fiducials.
Time frame: from date of fiducial placement to 12 months after completion of SBRT treatment
Reliability of Gated SBRT Treatments Utilizing SGRT vs. SGRT With Fiducials - Directional Shifts
Measured shift deltas for each of the directional (in cm; vertical, longitudinal, lateral) shifts were determined utilizing surface guided radiation therapy (SGRT, or SGRT + fiducials) based on target position at the time of verification imaging using cone beam computed tomography. This was recorded as numerical values in centimeters for each directional shift, as well as a calculated vector composite of the directional shifts. Reliability was measured with each fraction.
Time frame: from start of SBRT treatment to completion of SBRT treatment, median duration was 4 days
Reliability of Gated SBRT Treatments Utilizing SGRT vs. SGRT With Fiducials - Rotational Shifts
Measured shift deltas for each of the rotational (in degrees; roll, pitch, rotation) shifts were determined utilizing surface guided radiation therapy (SGRT, or SGRT + fiducials) based on target position at the time of verification imaging using cone beam computed tomography. This was recorded as numerical values in degrees for each rotational shift. Reliability was measured with each fraction.
Time frame: from start of SBRT treatment to completion of SBRT treatment, median duration was 4 days
Local Control of Treated Tumor(s)
The outcome will be measured as the duration of time from enrollment to progression of the subject's treated tumor(s)
Time frame: up to 24 months
Overall Survival
This outcome will be measured as the duration of time from the date of enrollment to the study to the date of death from any cause.
Time frame: approx. 2 years
Change From Baseline in MD Anderson Symptom Inventory - Lung Cancer (MDASI-LC) Total Symptom + Interference Score
The MDASI-LC Module includes 22 questions to assess the severity of multiple lung cancer-related symptoms and the impact of these symptoms on daily functioning. Scores for each item range from 0 to 10, where 0 indicates no symptoms and 10 indicates worst possible symptoms. Arithmetic mean of the items completed was calculated to determine a mean total symptom + interference score ranging from 0 to 10. The mean score is reported if more than 50% of the items are completed on a given administration. Change from baseline was calculated as the post baseline timepoint mean score minus the baseline mean score for each participant. As higher scores indicate worse symptoms and more interference at a given timepoint, if the change from baseline is a positive value, this indicates a worsening of symptoms at the post-baseline timepoint.
Time frame: From pre-SBRT to 1, 3, 6, and 12 months after the last treatment of SBRT (on average SBRT treatment lasted 4.8 days)
Number of Participants With Grade 2 or Higher Non-hematologic Toxicities Attributed to SBRT as Assessed by NCI CTCAE v.5.0
A binary variable was determined for each participant indicating whether the participant experienced at least one grade 2 or higher non-hematologic adverse event (according to NCI Common Terminology for Adverse Events version 5.0) during treatment or within 12 months after completion of SBRT that was determined to be related (possibly, probably, or definitely attributed) to SBRT.
Time frame: from date of SBRT start or fiducial placement to 12 months after completion of SBRT treatment (on average SBRT treatment lasted 4.8 days)
Number of Participants With Grade 2 or Higher Non-hematologic Toxicities Attributed to Fiducial Implantation as Assessed by NCI CTCAE v.5.0
A binary variable was determined for each participant indicating whether the participant experienced at least one grade 2 or higher non-hematologic adverse event (according to NCI Common Terminology for Adverse Events version 5.0) during treatment or within 12 months after completion of SBRT that was determined to be related (possibly, probably, or definitely attributed) to implantation of fiducials.
Time frame: from date of SBRT start or fiducial placement to 12 months after completion of SBRT treatment (on average SBRT treatment lasted 4.8 days)
SBRT Administration - Number of Fractions Received
Descriptive summary of SBRT administration. Number of fractions of SBRT the participant received on study.
Time frame: From enrollment to completion of SBRT treatment; SBRT treatment lasted on average 4.8 days
SBRT Administration - Total Dose Delivered
Descriptive summary of SBRT administration. Total dose (in Gray) of SBRT received.
Time frame: From enrollment to completion of SBRT treatment; SBRT treatment lasted on average 4.8 days
Pulmonary Function Test (PFT) Results at Baseline and 6 Months
Results from the PFTs, including forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1), and diffusing capacity of the lungs for carbon monoxide (DLCO), were captured as a percentage of the predicted normal values based on age, height, gender, and sex. FVC measures the total lung volume and capacity. FEV1 measures the speed of airflow. DLCO measures how well gases transfer from inside of lungs into bloodstream. PFTs were done pre-SBRT and 6 months after the last treatment of SBRT.
Time frame: pre-SBRT and 6 months after the last treatment of SBRT (on average SBRT treatment lasted 4.8 days)
| Milestone | Group 1 | Group 2 | Group 3 |
|---|---|---|---|
| Started | 15 | 25 | 5 |
| Completed | 0 | 0 | 0 |
| Not completed | 15 | 25 | 5 |
| Withdrew: Death | 11 | 11 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 |
| Withdrew: Still on study | 4 | 12 | 4 |
A binary variable was determined for each participant indicating whether the participant experienced at least one grade 2 or higher pulmonary adverse event (according to NCI Common Terminology for Adverse Events version 5.0) during treatment or within 12 months after completion of SBRT that was determined to be related (possibly, probably, or definitely attributed) to SBRT.
| Participants | Group 1 | Group 2 | Group 3 |
|---|---|---|---|
| Number of Participants With Grade 2 or Higher SBRT-related Pulmonary Toxicities as Assessed by NCI CTCAE v.5.0 | 1 | 1 | 0 |
A binary variable was determined for each participant indicating whether the participant experienced at least one grade 2 or higher pulmonary adverse event (according to NCI Common Terminology for Adverse Events version 5.0) during treatment or within 12 months after completion of SBRT that was determined to be related (possibly, probably, or definitely attributed) to implantation of fiducials.
| Participants | Group 3 |
|---|---|
| Number of Participants With Grade 2 or Higher Fiducial-related Pulmonary Toxicities as Assessed by NCI CTCAE v.5.0 | 0 |
Measured shift deltas for each of the directional (in cm; vertical, longitudinal, lateral) shifts were determined utilizing surface guided radiation therapy (SGRT, or SGRT + fiducials) based on target position at the time of verification imaging using cone beam computed tomography. This was recorded as numerical values in centimeters for each directional shift, as well as a calculated vector composite of the directional shifts. Reliability was measured with each fraction.
| cm | Group 2 | Group 3 |
|---|---|---|
| Vertical | 0.09 ± 0.02 | 0.10 ± 0.04 |
| Longitudinal | 0.16 ± 0.02 | 0.19 ± 0.06 |
| Lateral | 0.08 ± 0.02 | 0.08 ± 0.04 |
| Vector composite | 0.23 ± 0.03 | 0.24 ± 0.08 |
Measured shift deltas for each of the rotational (in degrees; roll, pitch, rotation) shifts were determined utilizing surface guided radiation therapy (SGRT, or SGRT + fiducials) based on target position at the time of verification imaging using cone beam computed tomography. This was recorded as numerical values in degrees for each rotational shift. Reliability was measured with each fraction.
| degrees | Group 2 | Group 3 |
|---|---|---|
| Roll | 0.20 ± 0.07 | 0.10 ± 0.17 |
| Pitch | 0.18 ± 0.06 | 0.17 ± 0.15 |
| Rotation | 0.08 ± 0.05 | 0.32 ± 0.13 |
The outcome will be measured as the duration of time from enrollment to progression of the subject's treated tumor(s)
Results for this outcome have not been posted.
This outcome will be measured as the duration of time from the date of enrollment to the study to the date of death from any cause.
Results for this outcome have not been posted.
The MDASI-LC Module includes 22 questions to assess the severity of multiple lung cancer-related symptoms and the impact of these symptoms on daily functioning. Scores for each item range from 0 to 10, where 0 indicates no symptoms and 10 indicates worst possible symptoms. Arithmetic mean of the items completed was calculated to determine a mean total symptom + interference score ranging from 0 to 10. The mean score is reported if more than 50% of the items are completed on a given administration. Change from baseline was calculated as the post baseline timepoint mean score minus the baseline mean score for each participant. As higher scores indicate worse symptoms and more interference at a given timepoint, if the change from baseline is a positive value, this indicates a worsening of symptoms at the post-baseline timepoint.
| score on a scale | Group 1 | Group 2 | Group 3 |
|---|---|---|---|
| Change from baseline to 1 month after SBRT | -0.70 ± 0.33 | -0.06 ± 0.26 | 0.83 ± 0.55 |
| Change from baseline to 3 months after SBRT | -0.38 ± 0.34 | -0.25 ± 0.28 | 0.78 ± 0.55 |
| Change from baseline to 6 months after SBRT | -0.74 ± 0.36 | -0.22 ± 0.28 | 0.17 ± 0.55 |
| Change from baseline to 12 months after SBRT | -0.80 ± 0.42 | 0.01 ± 0.29 | 0.68 ± 0.59 |
A binary variable was determined for each participant indicating whether the participant experienced at least one grade 2 or higher non-hematologic adverse event (according to NCI Common Terminology for Adverse Events version 5.0) during treatment or within 12 months after completion of SBRT that was determined to be related (possibly, probably, or definitely attributed) to SBRT.
| Participants | Group 1 | Group 2 | Group 3 |
|---|---|---|---|
| Number of Participants With Grade 2 or Higher Non-hematologic Toxicities Attributed to SBRT as Assessed by NCI CTCAE v.5.0 | 1 | 3 | 0 |
A binary variable was determined for each participant indicating whether the participant experienced at least one grade 2 or higher non-hematologic adverse event (according to NCI Common Terminology for Adverse Events version 5.0) during treatment or within 12 months after completion of SBRT that was determined to be related (possibly, probably, or definitely attributed) to implantation of fiducials.
| Participants | Group 3 |
|---|---|
| Number of Participants With Grade 2 or Higher Non-hematologic Toxicities Attributed to Fiducial Implantation as Assessed by NCI CTCAE v.5.0 | 0 |
Descriptive summary of SBRT administration. Number of fractions of SBRT the participant received on study.
| Participants | Group 1 | Group 2 | Group 3 |
|---|---|---|---|
| 1 fraction received | 0 | 1 | 0 |
| 3 fractions received | 13 | 23 | 5 |
| 5 fractions received | 2 | 1 | 0 |
Descriptive summary of SBRT administration. Total dose (in Gray) of SBRT received.
| Gray | Group 1 | Group 2 | Group 3 |
|---|---|---|---|
| SBRT Administration - Total Dose Delivered | 54 (50 to 55) | 54 (18 to 60) | 54 (54 to 54) |
Results from the PFTs, including forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1), and diffusing capacity of the lungs for carbon monoxide (DLCO), were captured as a percentage of the predicted normal values based on age, height, gender, and sex. FVC measures the total lung volume and capacity. FEV1 measures the speed of airflow. DLCO measures how well gases transfer from inside of lungs into bloodstream. PFTs were done pre-SBRT and 6 months after the last treatment of SBRT.
| % of predicted normal values | Group 1 | Group 2 | Group 3 |
|---|---|---|---|
| FVC % at baseline | 82 (42 to 132) | 94 (55 to 127) | 84 (49 to 100) |
| FVC % at 6 months after SBRT | 80 (64 to 90) | 95 (59 to 124) | 78 (61 to 111) |
| FEV1 % at baseline | 79 (18 to 102) | 75 (37 to 130) | 64 (36 to 71) |
| FEV1 % at 6 months after SBRT | 69 (51 to 88) | 84.5 (39 to 125) | 60 (42 to 79) |
| DLCO % at baseline | 54 (19 to 78) | 68 (28 to 118) | 51 (44 to 70) |
| DLCO % at 6 months after SBRT | 53 (30 to 76) | 67 (27 to 102) | 68 (34 to 84) |
Collected over From enrollment or fiducial implantation, during treatment, until 12 months after last treatment of SBRT (on average SBRT treatment lasted 4.8 days). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group 1 | 11/15 (73.3%) | 2/15 (13.3%) | 1/15 (6.7%) |
| Group 2 | 11/25 (44%) | 1/25 (4%) | 3/25 (12%) |
| Group 3 | 0/5 (0%) | 0/5 (0%) | 0/5 (0%) |
| Event | Group 1 | Group 2 | Group 3 |
|---|---|---|---|
| Lung infectionInfections and infestations | 1/15 | 0/25 | 0/5 |
| Respiratory, thoracic and mediastinal disorders - OtherRespiratory, thoracic and mediastinal disorders | 1/15 | 0/25 | 0/5 |
| Aortic injuryInjury, poisoning and procedural complications | 0/15 | 1/25 | 0/5 |
| Event | Group 1 | Group 2 | Group 3 |
|---|---|---|---|
| FatigueGeneral disorders and administration site conditions | 1/15 | 1/25 | 0/5 |
| Non-cardiac chest painGeneral disorders and administration site conditions | 1/15 | 0/25 | 0/5 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 1/15 | 1/25 | 0/5 |
| Dermatitis radiationInjury, poisoning and procedural complications | 0/15 | 1/25 | 0/5 |
| Age, Categorical(Participants) | Group 1 | Group 2 | Group 3 | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 1 | 2 | 2 | 5 |
| >=65 years | 14 | 23 | 3 | 40 |
| Age, Continuous(years) | Group 1 | Group 2 | Group 3 | Total |
|---|---|---|---|---|
| Median | 77 (54 to 89) | 76 (34 to 86) | 70 (56 to 72) | 76 (34 to 89) |
| Sex: Female, Male(Participants) | Group 1 | Group 2 | Group 3 | Total |
|---|---|---|---|---|
| Female | 7 | 8 | 4 | 19 |
| Male | 8 | 17 | 1 | 26 |
| Ethnicity (NIH/OMB)(Participants) | Group 1 | Group 2 | Group 3 | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 15 | 24 | 5 | 44 |
| Unknown or Not Reported | 0 | 1 | 0 | 1 |
| Race (NIH/OMB)(Participants) | Group 1 | Group 2 | Group 3 | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 2 | 1 | 0 | 3 |
| White | 13 | 22 | 5 | 40 |
| More than one race | 0 | 1 | 0 | 1 |
| Unknown or Not Reported | 0 | 1 | 0 | 1 |
| Region of Enrollment(participants) | Group 1 | Group 2 | Group 3 | Total |
|---|---|---|---|---|
| United States | 15 | 25 | 5 | 45 |
| Baseline MDASI-LC Total Symptom and Interference Score(score on a scale) | Group 1 | Group 2 | Group 3 | Total |
|---|---|---|---|---|
| Mean | 2.0 ± 1.5 | 1.9 ± 1.3 | 2.7 ± 1.8 | 2.0 ± 1.4 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Sep 2019 to primary completion in Oct 2025, 72 months.
Results were first posted in Oct 2026, 1 year after primary completion.
Of 871 non-industry interventional studies with no phase under Lung Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 69. This study's 72 months is above that.
Counting every sponsor, half of 922 studies reached it within 34 months; a quarter within 15 and three quarters within 67.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Wake Forest University Health Sciences →